KSCMS-Kwang Kon KOH
Kwang Kon KOH, MD, PhD, FACC Dr. KOH gratudated from Seoul National University, College of Medicine, Seoul, Korea in 1982. He had served as Visiting Scientist and Cardiology Consultant at Cardiology Branch, NHLBI, NIH, Maryland, USA. Dr. Koh is currently a Professor at Gachon University and Director of Cardiometabolic Syndrome Unit, Division of Cardiology, Gil Hospital, in South Korea and President, Korean Society of CardioMetabolic Syndrome, the Korean Society of Cardiology. Dr. Koh is currently an Associate Editor of the Circulation Journal (IF 3.544), an official scientific journal of the Japanese Circulation Society. He had served as Associate Editor of the International Journal of Cardiology (Feb 2006-Aug 2016). He is also the first or corresponding author of more than 210 papers in peer-reviewed Journals such as New England Journal of Medicine and Circulation; original articles, editorials, books, and review papers. He has also delivered a lecture at more than 109 professional international meetings including AHA 2003, 2004, 2005, 2012, 2014,2015,2017 ACC 2008, WCC 2008, 2010, 2012, 2014, ESC2013, 2014, 2015,2016 and at many first-rate medical schools including Brigham and Women’s hospital at Harvard, Stanford University, NIH, Baylor Medical School, and Oxford University. Dr. Koh received Established Investigator Award, 1999, Seoul National University School of Medicine Alumni Association and Scientific Achievement Award, 2002, Seoul National University School of Medicine, Internal Medicine Alumni Association and Emile von Bering Scientific Achievement Award, 2008, Korean Medical Association and AstraZeneca Scientific Achievement Award, 2014, Korean Society of Cardiology. Dr. Koh had served as International Subcommittee of CSSP (AHA Scientific Sessions 2014 and 2015 programming) and (ESC Scientific Sessions 2014 and 2015 programming). His research focuses on the biological effects of Estrogen in postmenopausal women and Therapeutic interventions in patients with hyperlipidemia using HMG CoA Reductase Inhibitors (Statins) and Fenofibrate and Therapeutic interventions using ACE Inhibitors or Angiotensin II type 1 Receptor Blockers (ARBs) in patients with risk factors or established coronary artery disease to prevent or retard the progression of atherosclerosis, particularly with regard to vascular wall; endothelium-dependent vasodilation; inflammation; hemostasis; and metabolic effects such as adiponectin and insulin resistance. Particularly, Dr. Koh first suggested a hypothesis that statins may increase the risk of new-onset type 2 diabetes mellitus in 2004 and has contributed to confirm his original hypothesis in the mechanistic clinical studies over 16 years with many publications in the prestigious Journals. Because of his achievement, USA FDA and EU put the warning note on the statins label in March 2012. Of note, he first also suggested a hypothesis- statin-based combination therapy for treatment of atherosclerosis prevention with minimizing the risk of statins and set up this session in ACC 2008 and WCC 2010.
Dyslipidemia and Atherosclerosis
Diabetes and Metabolism
Prevention, Risk Control, Rehabilitation and Disease Management
This website is optimized for Chrome and Internet Explorer 11.